Exploring the Pitfalls of Patent Amendments

Navigating the pathways of patent applications can be daunting. While novelty and inventive step of a patent usually dominate the spotlight, there is a lurking detail that often slips through the cracks but can make or break your application: "going beyond the scope of the original disclosure." This article will analyze the matter of "going beyond the scope of the original disclosure" from various perspectives, including the legislative intent and the timing of amendments. We will also illustrate the practice determination standards with actual cases to offer you a reliable guide to champion future patent prosecution and invalidation procedures.

The patent system seeks a balance between patentees and the public, aiming to encourage innovation and provide inventors with their due monopoly, but never at the cost of public interest. While the Patent Law of the People's Republic of China (hereinafter referred to as Patent Law) does permit amendments, it wraps them in strict constraints. This is the legislative intent behind the legal provisions on the restriction of amendments.

The patent realm operates on a quid pro quo principle: "protection in return for disclosure." If applicants were allowed to include content not disclosed before the application date, or the priority date, if any, it would enable protection for subject matters without disclosure on legitimate date, which would unfairly tip the scales against the public interest. Therefore, according to Article 33 of the Patent Law and Paragraph 1 of Article 43 of the Rules for the Implementation of the Patent Law of the People's Republic of China (hereinafter referred to as Implementation Rules), applicants may amend their patent application documents, provided that amendments to the invention and utility model patent application documents do not go beyond the scope of disclosure in the original description and claims.

The Guidelines for Patent Examination further clarify this by detailing two acceptable amendment categories: one is the content disclosed in the words of the original description and claims, and the other is content that can be directly and unambiguously determined based on the content disclosed in the terms of the original description and claims, as well as the drawings attached to the description. During both the substantive examination and the reexamination of patent applications and the examination of the invalidation process, "going beyond the scope of the original disclosure" is one of the first objects of examination and forms the basis for determining the text to be examined, holding a position of vital importance.

Multiple amendments are permitted during the patent prosecution and invalidation procedures to allow applicants or patentees to refine their application or patent documents. These amendments can be made voluntarily, where applicants anticipate and address potential issues, or in response, where amendments respond to office actions. Regardless of the approach, certain key timings and contexts guide them:

Article 28 and Article 41 of the Patent Cooperation Treaty (PCT):

Amendment Timing: Upon entering the national phase in China under the PCT.

Amendment Type: Amendments can be made to the claims, descriptions, and drawings.

Rule 51(1) of the Implementation Rules:

Amendment Timing: When requesting substantive examination or within three months of receiving the relevant notification from the China National Intellectual Property Association (CNIPA).

Amendment Type: Amendments can be made to the claims, descriptions, and drawings.

Rule 43(1) of the Implementation Rules:

Amendment Timing: When submitting a divisional application.

Amendment Type: Amendments can be made to the claims, descriptions, and drawings.

Rule 51(3) of the Implementation Rules:

Amendment Timing: Responding to the Office Action.

Amendment Type: Amendments can be made in response to the objections raised in the Office Action.

Rule 69(1) of the Implementation Rules:

Amendment Timing: During the invalidation process.

Amendment Type: Amendments can be made solely to the claims.

Whether making voluntary or reactive changes, the golden rule remains: never go beyond the original scope. In the following sections, we will use specific cases as examples to analyze the criteria for grasping the legal provisions related to this rule in actual practice.

Case 1: Patent Amendments and Their Implications

This case involves a method for detecting fluid (e.g., hydraulic and diesel fuel) injection in patients, with the primary objective being to facilitate the timely identification of potentially harmful fluids injected into the human body and prevent treatment delays.

Claim 1 of the patent:

A method for detecting fluid injection in a patient, the method including the steps of: providing a fluid storage tank; providing fluid for use in machinery and adding said fluid to the fluid storage tank; providing a fluorescent dye and adding the fluorescent dye to the fluid such that the fluid fluoresces in the presence of blue light or ultraviolet light ultraviolet light; and possible fluid injection occurring in a patient.

The examiner objected this claim on the grounds that the "method for detecting fluid injection in patients" is applied to living human or animal bodies, including ex vivo samples, and directly informs whether a fluid injection has occurred in the patient. This method directly reflects the diagnosis of the disease or the health condition of the patient. As such, it appeared to fall within the purview of diagnostic methods stipulated in Article 25, Paragraph 1, Item (3) of the Patent Law, rendering it ineligible for patent protection. In response to the Office Action, the applicant strategically revised the claim. They removed the term "patient" and coined it "a method for detecting hydraulic fluid at a potential fluid injection location." They also limited the scope of the fluorescent dye, specifying it for patient injection, paving the way for the patent's grant.

During the subsequent patent invalidation procedure, representing the petitioner, we emphasized that removing the term "patient" from the subject matter of Claim 1 expanded its protection scope. Additionally, since the original Claim 1 did not specify that the fluorescent dye was "suitable for injection into patients," such an amendment does not comply with Article 33 of the Patent Law.

On the flip side, the CNIPA maintained that although the designation "for patients" had been deleted from the subject matter in the claim, the amendment was constrained by adding "a fluorescent dye suitable for patients" to the specified fluid rather than any fluorescent dye. Thus, considering the totality of the technical features defined in Claim 1, the CNIPA concluded that the amendment did not extend beyond the original scope of the claim. We then filed an appeal before the Beijing Intellectual Property Cour, and a disagreement arose between the CNIPA and court over the applicant's amendments.

The Beijing Intellectual Property Court weighed in, contending that omitting "patient," the method's applicability broadened. Even with the amendment specifying the "fluorescent dye suitable for injection into patients," we argued that the limitation pertains to the characteristics of the fluorescent dye itself, not to the entities into which it is to be injected. This specification of the dye's suitability for injection into patients restricts its properties rather than its application, allowing for its potential use in contexts other than human patients. Ultimately, the first-instance judge ruled us in favor.

This case exemplifies the complexity of patent amendments, where applicants make revisions in response to an examiner's objection, a reactive measure that may lead to further scrutiny. It highlights that even if amendments are accepted and the patent is granted, challenges can still arise in the invalidation phase, as evidenced by this case where the substantive examination accepted the changes. Still, the administrative litigation phase determined the amendments exceeded the original scope. It is a cautionary tale that even with additional limitations set on other features, the resultant scope of protection may not align with the original disclosure.

Here is a nugget of wisdom for future applicants: tackle such amendments with care. Even a strategic restriction of other features may not equate to the scope initially recorded. And sometimes, instead of making hasty amendments based on examination remarks, a well-framed argument might do the trick.

Case 2: Merging Embodiments in Divisional Patent Applications

The second case relates to a divisional application, of which the parent application recites four separate embodiments regarding cell reselection in the description. When filing the divisional application, the first and the fourth embodiments in the description were combined into a new independent claim. The first embodiment involves setting a timer for the priority of cell reselection, which expires when the timer does; the fourth pertains to reselection to a CSG cell with extended coverage. The divisional application passed the examination and was allowed.

When we, representing the invalidation petitioner against this patent, went through the history documents, it becomes evident that the two embodiments address different technical aspects within cell reselection. The consolidated claim within the granted patent makes this clear: cell reselection priority is utilized to execute reselection to the hybrid CSG cell, provided that the timer has not yet expired and the hybrid CSG cell indicator includes an identifier corresponding to the CSG cell ID.

During the invalidation proceedings, the CNIPA inferred that the steps following the condition where the timer has not yet expired, as mentioned in the description, pertain solely to the cell reselection priority and do not encompass the coverage extension CSG cell. Additionally, the claims depict a clear sequence of operations not present in the original parent application documents. Consequently, CNIPA sided with our viewpoint.

In this case, although the first and the fourth embodiments are formally documented in the original parent application, the applicant's amendment merges the two. The technical features influence each other, diverging substantially from a basic superimposition of embodiments, thereby evolving into a brand-new tech mix. Notably, such amendments do not find favor in the current patent examination practices in China. When drafting a divisional patent application, applicants should duly consider the feasibility of merging embodiments and provide extensive elaboration in the embodiments, ensuring flexibility for potential amendments.

Through the above two cases, we can discern that, during the substantive examination of patent applications and invalidation process of patents in China, the examination standard for "going beyond the scope of the original disclosure" is quite strict, with a high demand for the criteria of "directly and unambiguously determinable." When amending application documents, especially the claims, it is essential not only to consider the technical meaning of each technical feature before and after the amendment but also to comprehensively assess the impact of the amendment on the overall embodiment. Any amendments that result in a new embodiment may not expect a warm reception.

At its core, the documentation of the original text is crucial. Although it is challenging to contemplate every possible mode of the amendment during the initial drafting, deploying embodiments as outreaching as possible is still advisable to support subsequent possible amendments to the greatest extent. Crafting a solid patent? It is an art and science combined. As patent agents in China, we look forward to leveraging our professional knowledge and practical experience to provide robust legal support, safeguarding the legitimate interests of the parties concerned.